Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Sources Sought opportunity from Department Of Defense was posted on March 8, 2021. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Establishment of BPAs for Polyvalent Snake Antivenom

Closed
W9114F-21-SS-0001Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414
Federal
Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)
Solicitation # 12639527R0001
Solicitation 12639527R0001 is a request for proposals issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an Indefinite Delivery Indefinite Quantity (IDIQ) contract. The requirement covers the purchase, storage, and production of Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC), the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract has a ceiling price of 800 million dollars and a long-term performance horizon, featuring five one-year ordering periods starting approximately December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The scope of work requires the contractor to produce VAC capable of yielding at least 1.0 million doses and maintain these materials on their premises under strict quality control and temperature standards. Because live FMDV is a Tier 1 Select Agent, the contractor must hold a select agent authorization issued by CDC/APHIS. Finished vaccines must be packaged to maintain temperatures between 2 to 8 degrees Celsius for 24 hours and include electronic temperature monitors. Award will be based on the most advantageous offer considering technical capability, past performance from the last five years, and fair and reasonable pricing. Proposals must be submitted electronically to Stephen Tees by November 10, 2026, at 1700 CT, organized into four separate volumes.
Mrpbs Minneapolis Mn

POSTED

20 days ago

DEADLINE

in 21 days

General Info

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Place of Performance

Pirmasens, AE, 66953, DEU

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

Sources Sought

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → W40M Mrco Europe
Contacts1 person available
OfficeAPO, AE, 09180-0402, USA
Office AddressAPO, AE, 09180-0402, USA
Contacts
Donna Kabatek

Full Description

Show more
THIS IS A SOURCES SOUGHT ANNOUNCEMENT ONLY. This notice does not constitute a commitment by the Government. All information submitted in response to this announcement is voluntary, and the Government will not pay for information requested nor will it compensate any respondent for any cost incurred in developing information provided to the Government. The Regional Health Contracting Office-Europe (RHCO-E), located in Landstuhl, Germany, is interested in establishing Basic Purchase Agreements (BPAs) to provide POLYSERP. The period of performance for the BPA will be five years from the date of issue. The BPA must provide for the following requirements: POLYSERP is a polyvalent snake antivenom placed into the body designed for the treatment of envenomation as are result of a snake bite by various numbers of snake species across the Middle East and North Africa. POLYSERP is designed for austere conditions, meeting the requirements of medical professionals in African/Middle Eastern theater of operations in that it can be carried in a pack for multiple months in temperatures exceeding high temperatures without any loss of potency; therefore, not requiring refrigeration like other anti-venoms. The following performance/delivery/specification guidelines apply: 1) Shall be shipped within 5 business days of call, delivered to the USAMMCE, Receiving Branch in Pirmasens, Germany. Desired delivery is 10 business days after order placed. Delays due to non-availability of product will be considered on a case-by-case basis and at the Government's discretion. 2) Each package shall contain 6 vials per package/box. 3) Shall not need to be refrigerated, but instead the material shall be a freeze-dried for field use, stable in severe temperature conditions, allowing storage up to 40C (104F) for a maximum period of 6 months without losing potency. 4) Shall be licensed for use on humans by a government sponsored regulator health agency. 5) Shall be a polyvalent, broad spectrum, treatment covering 25 species of snake species venoms across Sub-Saharan Africa, including but not limited to African adders, spitting and non-spitting Cobras, saw-scaled vipers, Mambas, boomslang and desert horned vipers, enabling medical providers to treat patient based on the clinical syndrome of envenomation rather than identify the snake. 6) Shall be designed to be administered by direct IV push in low resource environments. We are seeking qualified companies with whom to establish a BPA. Receiving a BPA will be based upon the company's ability to adequately demonstrate it can provide the above-described POLYSERP which meets the stated criteria. Before establishing a BPA with any interested company, the Government will seek to identify responsible companies capable of providing the required supplies. No more than four qualified companies indicating an interest will be issued a BPA. In order to identify responsible vendors we will also review available past performance. Once BPAs are established, each individual requirement for POLYSERP will be competed amongst the BPA contractors and an order issued to the contractor offering the lowest price on that particular order. Each order will be competed in the same manner. There is no guarantee that a contractor will receive any orders against their BPA. Companies interested in receiving a BPA must provide evidence of their qualifications for meeting the requirements as specified above. In addition, any companies located outside of the European Union must also address how they will meet the requirement to deliver acceptable product within the stated timelines. Written responses will not be returned. If your firm is capable and qualified to provide the item, respond in writing to the point of contact indicated within this announcement no later than 19 March 2021. All interested business concerns shall indicate their interest in a potential BPA by providing the company name, mailing address, telephone number, CAGE code, DUNS number or Unique Entity Identifier and email address to the point of contact. Interested business concerns shall also submit appropriate written information and/or data supporting their capability to perform the required services. For the purpose of a potential BPA, the North American Industrial Classification Code is 325414 and the applicable size standard is 1,250. Orders written against a BPA will be firm-fixed price. The primary contact point is Donna Kabatek, +49 (0)6371 9464 6550. E-mail responses to donna.m.kabatek.civ@mail.mil .

More opportunities from Department Of Defense → W40M Mrco Europe

Same awarding agency

NAICS: 325413
Federal
Blood Chemistry Testing - Cost Per Reportable Result
Solicitation # W9114F-26-Q-A009
The Medical Readiness Contracting Office-Europe is soliciting a Fixed-Price Indefinite Delivery/Indefinite Quantity contract for one automated chemistry analyzer and associated consumables to support the laboratory mission at the U.S. Army Health Clinic in Vicenza, Italy. Under a Cost Per Reportable Result pricing structure, the successful offeror will provide all new equipment, reagents, consumables, controls, and necessary maintenance. The contract includes a two-month phase-in period from January 2, 2026, to February 28, 2026, followed by an ordering period from March 1, 2026, through December 31, 2030. The estimated annual clinical chemistry workload is 42,595 tests. Technical requirements specify that the analyzer must be FDA-approved, capable of measuring analytes from a 300-microliter sample, and equipped with an uninterruptible power supply providing seven minutes of power. The system must have a current Authorization to Operate for interfacing with the Laboratory Information System and comply with the Risk Management Framework for DOD IT. The contractor is responsible for providing initial on-site operator training in English and ensuring all reagents are delivered at the proper storage temperature. Award will be based on the Lowest Price Technically Acceptable evaluation process under Simplified Acquisition Procedures, with the solicitation open for full competition under NAICS code 325413.
In-Vitro Diagnostic Substance Manufacturing

POSTED

12 months ago

DEADLINE

N/A
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS